Latest News for: dlb

Edit

Dolby Laboratories (NYSE:DLB) Reports Bullish Q4 CY2025

The Call 29 Jan 2026
DLB) reported revenue ahead of Wall Streets expectations in Q4 CY2025, but sales fell by 2.9% year on year to $346.7 million ... Dolby Laboratories (DLB) Q4 CY2025 Highlights. ... DLB) designs and licenses ...
Edit

Earnings To Watch: Dolby Laboratories (DLB) Reports Q4 Results Tomorrow

The Call 28 Jan 2026
Audio and video technology company Dolby Laboratories (NYSE. DLB) will be announcing earnings results this Thursday after the bell. Here’s what to expect ... Adjusted earnings are expected to come in at $0.99 per share ... More News. View More ... Via MarketBeat ... .
Edit

Dolby Laboratories (NYSE:DLB) Surprises With Q3 CY2025 Sales

The Call 31 Dec 2025
DLB) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $307 million ... Dolby Laboratories (DLB) Q3 CY2025 Highlights. ... DLB) designs and licenses ...
Edit

Accenture to Acquire Majority Stake in DLB to Expand Capital Projects Capabilities for End-to-End Data ...

Business Wire 17 Dec 2025
NEW YORK & NEPTUNE, N.J.--(BUSINESS WIRE)--Accenture signed an agreement to acquire a majority stake (65%) in US-based AI data center engineering and consulting firm DLB Associates ... .
Edit

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) (Form 8-K) (Cervomed Inc)

Public Technologies 05 Dec 2025
Dementia with Lewy Bodies (DLB) ... "These results highlight the utility of biomarkers such as plasma GFAP and the Aβ42/40 ratio in DLB and suggest that neflamapimod may be acting on the underlying disease process.
  • 1

Article Search

tools
×
×
×
×